Form 4: Enanta CEO Sells Shares for Tax Obligations

Enanta Pharmaceuticals' President and CEO, Jay R. Luly, sold 4,743 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Summary

• Jay R. Luly, President and CEO, and a Director of Enanta Pharmaceuticals Inc. (ENTA), reported a transaction on December 5, 2025.
• Luly sold 4,743 shares of Enanta Pharmaceuticals Common Stock.
• The shares were sold at a weighted-average price of $14.23 per share, with individual transactions ranging from $13.89 to $14.46.
• The sale was a "sell to cover" transaction, specifically to satisfy tax withholding obligations arising from the settlement of a restricted stock unit award granted on November 23, 2022.
• This transaction was not a discretionary sale by the reporting person.
• Following the reported transaction, Jay R. Luly beneficially owns 858,026 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is a neutral event and does not reflect management's sentiment on the company's future prospects.

Positives

• The underlying restricted stock unit award, granted on November 23, 2022, represents a form of long-term incentive compensation for the CEO.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.
• The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape analysis.

Related Party Transactions

• The transaction involves the sale of company stock by a key executive (President and CEO) to cover tax obligations related to a compensation award, which is a common type of insider transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is non-discretionary and for tax purposes, not indicative of a change in management's confidence.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The reporting person has committed to providing full information regarding the number of shares sold at each separate price within the reported range upon request.

Key Dates

Recommendation

This Form 4 reports a non-discretionary 'sell to cover' transaction by the CEO to satisfy tax obligations on vested restricted stock units. Such transactions are routine and do not typically signal a change in the executive's outlook on the company's fundamentals or future stock performance. Therefore, it provides insufficient information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, Insider Transaction, Jay R. Luly, CEO, Director, Stock Sale, Restricted Stock Units, Tax Withholding, Sell to Cover